Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|November 17, 2017

Integrated Analytical Software Solutions for Clinical and Regulatory Processes

MasterControl has added three new cloud-based analytical solutions to its MasterControl Version 11.7 software for clinical managers and regulatory/submissions professionals.

MasterControl, a provider of integrated software solutions, added three new cloud-based analytical solutions to its MasterControl Version 11.7 software. The eTMF Manager is a software system that automates, centralizes, and standardizes the trial master file process for clinical studies. Registrations, a submission system for product registration and 510(k) device submission management, automates manual or hybrid processes, tracks various requirements globally, and creates transparency for the monitoring of submission bottlenecks. Registrations for eCTD is a publishing software for product registration and electronic common technical documents management. According to the company, these systems are suited to provide clinical managers, as well as regulatory and submissions professionals, the tools and methods needed to improve product time to market.

The updated version includes an analytic engine by JReport, a customizable reporting and business intelligence solution, and allows users to view, filter, and interact with their data more than previous versions of the software. Expanded capabilities include a stylized preview of reports in the form of icons, an interactive editor mode, and two user modes. The editor mode enables users to change column size, add or remove columns, create new data columns for statistics such as percentages and column math, and create new data within the report. Additionally, users can add or subtract columns, images, groupings, summary fields, calculated fields, filters, labels, and graphics.

Source: MasterControl


Related to this article

The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.